As you will see, the reviewers appreciate your data and only have a few suggestions on how to further strengthen your work. We would be thus happy to publish your paper in Life Science Alliance pending final revisions to address the comments raised by the reviewers as well as the following editorial points:
-please deposit the whole exome sequencing data in a repository (https://ega-archive.org or https://www.ncbi.nlm.nih.gov/clinvar/) -please add the description for supplementary figure S6E to the legend -please add the missing panel 'D' to supplementary figure S7 -please upload all supplementary figures as individual files To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex You will be guided to complete the submission of your revised manuscript and to fill in all necessary information.
To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.
A. FINAL FILES:
These items are required for acceptance.
--An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
--High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, http://life-sciencealliance.org/authorguide --Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.
B. MANUSCRIPT ORGANIZATION AND FORMATTING:
Full guidelines are available on our Instructions for Authors page, http://life-sciencealliance.org/authorguide We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files. **Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.** **It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.** **The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.** **Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of this transparent process, please let us know immediately.** Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.
Sincerely, Andrea Leibfried, PhD Executive Editor Life Science Alliance Meyerhofstr. 1 69117 Heidelberg, Germany t +49 6221 8891 502 e a.leibfried@life-science-alliance.org www.life-science-alliance.org
Suzuki et al. report on two unrelated families with loricrin keratoderma where two different pathogenic germline variants were identified in LOR. The probands were exhibiting dozens of clinically and histologically normalized skin areas in which the authors demonstrated that the causal variants were corrected. In the normalized skin spots,the authors also identified loss-ofheterozygosity on chromosome 1q from regions centrometic of LOR to the telomere. In contrast, the affected skin did not show any LOH. The authors therefore proposed that somatic recombination is the mechanism for the reversion of the LOR mutations. Based on in vitro studies the authors furthermore demonstrate that the reversion confers a growth and/or survival advantage to cells in vitro.
The authors demonstrate for the first time the occurrence of somatic revertant mosaicim in LOR. The data is solid and the manuscript is well written.
Minor comment
In the material and methods there is limited amount of information how the whole exome sequencing and analysis was performed. Was only the proband sequenced or were additional family members included in the analysis? Was in silico panels used? How was the filtering of variants performed?
Reviewer #2 (Comments to the Authors (Required)):
This is a well-written and illustrated account of the phenomenon of revertant mosaicism occurring in the setting of a skin disease, loricrin keratoderma, an autosomal dominant disorder in which heterozygous frameshift mutations in LOR usually result in an arginine rich tail to the protein, nuclear retention of the mutant protein, and the disruption to the cornification process in skin. The clinical, skin microscopy and functional data collectively provide new insight into this observation. Minor comments only.
[1] In the introduction, bottom of page 4, it would be helpful to mention the specific genes involved since there are at least 2 genes showing RM in junctional EB (COL17A1 and LAMB3) and two in IWC (KRT1 and KRT10).
[2] Perhaps the extrapolation to therapy for patients should be downplayed a bit (abstract and discussion). Thus far, the most successful translation (with patient benefit) has been punch grafting for LAMB3 reported 5 years ago. 
Answer:
In accordance with the editor's suggestion, we have (1) modified the legend for Figure   S6 to add the description for Figure S6E , (2) added Figure S7D , and (3) uploaded all supplementary figures as individual files. Unfortunately, we failed to obtain informed consent from the patient to deposit the whole exome sequencing data in a public repository, although he agreed with us to publish his clinical data including his genetic results in scientific journals. We have also reformatted our manuscript to meet the journal's requirements for a research article. We thank the reviewer for the positive and supportive comments. We performed whole exome sequencing in 3 affected and 2 unaffected individuals in the family 1 without using in silico panels. Because the diagnosis of loricrin keratoderma was clinically and histologically suspected, we could easily identify the pathogenic mutation in LOR in this family. The revised manuscript now mentions these points and the filtering strategy used in this study as follows:
Reviewer #1:

Suzuki et al. report on two unrelated families with loricrin keratoderma where two different pathogenic germline variants were identified in LOR. The probands were exhibiting dozens of clinically and histologically normalized skin areas in which the
Results, 1 st paragraph "Whole-exome and Sanger sequencing in 3 affected and 2 unaffected individuals in the family revealed that the affected individuals were all heterozygous for a 1-bp insertion mutation in LOR, c.545_546insG (p.Gly183ArgfsTer153) (Fig 1G) , which had previously been reported to cause LK (Song et al, 2008) , further verifying the diagnosis of LK. By contrast, the unaffected individuals were both wild-type for the mutation."
Materials and Methods, "Whole-exome sequencing"
"Following the enrichment of coding regions and intron/exon boundaries using the SureSelect Human All Exon V4 Kit (Agilent Technologies), whole-exome sequencing was performed on the HiSeq 2000 platform (Illumina) with 100-bp paired-end reads to a median coverage of 100×. The sequence data were analysed and annotated using (Gudmundsson et al, 2017; Jonkman & Pasmooij, 2009; Lim et al, 2017; van den Akker et al, 2018) ."
Comment #2:
Perhaps the extrapolation to therapy for patients should be downplayed a bit (abstract and discussion). Thus far, the most successful translation (with patient benefit) has been punch grafting for LAMB3 reported 5 years ago.
Answer:
We fully understand the reviewer's concern. In accordance with the reviewer's suggestion, we have revised the manuscript as shown below.
Abstract
"Nevertheless, the identification of revertant mosaicism in LK might pave the way for revertant therapy for this intractable disease." Discussion, 3 rd paragraph "Future research into the molecular basis of revertant mosaicism might hold potential to benefit patients with LK and/or other currently intractable genetic diseases."
